CE Mark approval granted for Roche's Keytruda companion diagnostic

Roche (SIX:ROG; OTCQX:RHHBY) received CE Mark approval for its Ventana PD-L1 (SP263) Assay to identify metastatic non-small cell lung cancer (NSCLC) patients who are eligible for treatment with Keytruda pembrolizumab. The assay already has CE Mark approval as a complementary diagnostic for Opdivo nivolumab to treat NSCLC...